Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetology & Metabolic Syndrome
Published in: Diabetology & Metabolic Syndrome 1/2021

Open Access 01-12-2021 | Arterial Diseases | Research

Gut related inflammation and cardiorespiratory fitness in patients with CAD and type 2 diabetes: a sub-study of a randomized controlled trial on exercise training

Authors: Susanne Kristine Aune, Rune Byrkjeland, Svein Solheim, Harald Arnesen, Marius Trøseid, Ayodeji Awoyemi, Ingebjørg Seljeflot, Ragnhild Helseth

Published in: Diabetology & Metabolic Syndrome | Issue 1/2021

Login to get access

Abstract

Aim

Gut leakage has been shown to associate with low-grade inflammation and lower cardiorespiratory fitness in diabetic subjects. We aimed to investigate whether gut leakage markers related to cardiorespiratory fitness in patients with both coronary artery disease and type 2 diabetes, and whether these were affected by long-term exercise training.

Methods

Patients with angiographically verified coronary artery disease and type 2 diabetes mellitus (n = 137) were randomized to either 12 months exercise intervention or conventional follow-up. A cardiopulmonary exercise test and fasting blood samples were obtained before and after intervention to assess VO2peak and the biomarkers soluble CD14, lipopolysaccharide-binding protein and intestinal fatty-acid binding protein as markers of gut leakage.

Results

114 patients completed the intervention satisfactory. VO2peak correlated inversely to sCD14 (r = − 0.248, p = 0.004) at baseline. Dividing sCD14 into quartiles (Q), VO2peak was significantly higher in Q1 vs. Q2–4 (p = 0.001), and patients in Q2-4 (sCD14 > 1300 ng/mL) had an OR of 2.9 (95% CI 1.2–7.0) of having VO2peak below median (< 23.8 ml/kg/min) at baseline. There were no statistically significant differences in changes in gut leakage markers between the two randomized groups (all p > 0.05) after 12 months.

Conclusions

Cardiorespiratory fitness related inversely to sCD14, suggesting physical capacity to be associated with gut leakage in patients with CAD and T2DM. Long-term exercise training did not affect circulating gut leakage markers in our population.
Trial registration NCT01232608, Registered 02 November 2010—Retrospectively registered at https://​clinicaltrials.​gov/​ct2/​show/​NCT01232608?​term=​NCT01232608&​draw=​2&​rank=​1
Appendix
Available only for authorised users
Literature
1.
Ascher S, Reinhardt C. The gut microbiota: an emerging risk factor for cardiovascular and cerebrovascular disease. Eur J Immunol. 2018;48(4):564–75.CrossRef
2.
Saad MJ, Santos A, Prada PO. Linking gut microbiota and inflammation to obesity and insulin resistance. Physiology. 2016;31(4):283–93.CrossRef
3.
4.
Płóciennikowska A, Hromada-Judycka A, Borzęcka K, Kwiatkowska KJC, Sciences ML. Co-operation of TLR4 and raft proteins in LPS-induced pro-inflammatory signaling. Cell Mol Life Sci. 2015;72(3):557–81.CrossRef
5.
Moreno-Navarrete JM, Ortega F, Serino M, Luche E, Waget A, Pardo G, et al. Circulating lipopolysaccharide-binding protein (LBP) as a marker of obesity-related insulin resistance. Int J Obes. 2012;36(11):1442–9.CrossRef
6.
Reiner AP, Lange EM, Jenny NS, Chaves PH, Ellis J, Li J, et al. Soluble CD14: genomewide association analysis and relationship to cardiovascular risk and mortality in older adults. Arterioscler Thromb Vasc Biol. 2013;33(1):158–64.CrossRef
7.
Lepper PM, Schumann C, Triantafilou K, Rasche FM, Schuster T, Frank H, et al. Association of lipopolysaccharide-binding protein and coronary artery disease in men. J Am Coll Cardiol. 2007;50(1):25–31.CrossRef
8.
Battson ML, Lee DM, Weir TL, Gentile CL. The gut microbiota as a novel regulator of cardiovascular function and disease. J Nutr Biochem. 2018;56:1–15.CrossRef
9.
Shive CL, Jiang W, Anthony DD, Lederman MM. Soluble CD14 is a nonspecific marker of monocyte activation. AIDS. 2015;29(10):1263–5.CrossRef
10.
Timmermans K, Sir O, Kox M, Vaneker M, de Jong C, Gerretsen J, et al. Circulating iFABP levels as a marker of intestinal damage in trauma patients. Shock. 2015;43(2):117–20.CrossRef
11.
Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315–81.CrossRef
12.
Codella R, Ialacqua M, Terruzzi I, Luzi L. May the force be with you: why resistance training is essential for subjects with type 2 diabetes mellitus without complications. Endocrine. 2018;62(1):14–25.CrossRef
13.
Monda V, Villano I, Messina A, Valenzano A, Esposito T, Moscatelli F, et al. Exercise modifies the gut microbiota with positive health effects. Oxid Med Cell Longev. 2017;2017:3831972.CrossRef
14.
Estaki M, Pither J, Baumeister P, Little JP, Gill SK, Ghosh S, et al. Cardiorespiratory fitness as a predictor of intestinal microbial diversity and distinct metagenomic functions. Microbiome. 2016;4(1):42.CrossRef
15.
Motiani KK, Collado MC, Eskelinen JJ, Virtanen KA, LÖyttyniemi E, Salminen S, et al. Exercise training modulates gut microbiota profile and improves endotoxemia. Med Sci Sports Exerc. 2020;52(1):94–104.CrossRef
16.
Byrkjeland R, Njerve IU, Anderssen S, Arnesen H, Seljeflot I, Solheim S. Effects of exercise training on HbA1c and VO2peak in patients with type 2 diabetes and coronary artery disease: a randomised clinical trial. Diab Vasc Dis Res. 2015;12(5):325–33.CrossRef
17.
Balke B, Ware RW. An experimental study of physical fitness of Air Force personnel. UN Armed Forces Med J. 1959;10(6):675–88.
18.
Byrkjeland R, Edvardsen E, Njerve IU, Arnesen H, Seljeflot I, Solheim S. Insulin levels and HOMA index are associated with exercise capacity in patients with type 2 diabetes and coronary artery disease. Diabetol Metab Syndr. 2014;6(1):36.CrossRef
19.
Wasserman K. Principles of exercise testing and interpretation : including pathophysiology and clinical applications. 5th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2012.
20.
21.
Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27(6):1487–95.CrossRef
22.
Pugin J, Schurer-Maly CC, Leturcq D, Moriarty A, Ulevitch RJ, Tobias PS. Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14. Proc Natl Acad Sci USA. 1993;90(7):2744–8.CrossRef
23.
Wedell-Neergaard A-S, Krogh-Madsen R, Petersen GL, Hansen ÅM, Pedersen BK, Lund R, et al. Cardiorespiratory fitness and the metabolic syndrome: roles of inflammation and abdominal obesity. PloS ONE. 2018;13(3):e0194991.CrossRef
24.
Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract. 2014;105(2):141–50.CrossRef
25.
Awoyemi A, Troseid M, Arnesen H, Solheim S, Seljeflot I. Markers of metabolic endotoxemia as related to metabolic syndrome in an elderly male population at high cardiovascular risk: a cross-sectional study. Diabetol Metab Syndr. 2018;10:59.CrossRef
26.
Marwick TH, Hordern MD, Miller T, Chyun DA, Bertoni AG, Blumenthal RS, et al. Exercise training for type 2 diabetes mellitus: impact on cardiovascular risk: a scientific statement from the American Heart Association. Circulation. 2009;119(25):3244–62.CrossRef
27.
Pan B, Ge L, Xun YQ, Chen YJ, Gao CY, Han X, et al. Exercise training modalities in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. Int J Behav Nutr Phys Act. 2018;15(1):72.CrossRef
28.
Minamii T, Nogami M, Ogawa W. Mechanisms of metformin action: in and out of the gut. J Diabetes Investig. 2018;9(4):701–3.CrossRef
29.
Montinari MR, Minelli S, De Caterina R. The first 3500 years of aspirin history from its roots—a concise summary. Vascul Pharmacol. 2019;113:1–8.CrossRef
30.
Yaribeygi H, Atkin SL, Pirro M, Sahebkar A. A review of the anti-inflammatory properties of antidiabetic agents providing protective effects against vascular complications in diabetes. J Cell Physiol. 2019;234(6):8286–94.CrossRef
31.
Moreira APB, Texeira TFS, Ferreira AB, Peluzio MdCG, Alfenas RdCG. Influence of a high-fat diet on gut microbiota, intestinal permeability and metabolic endotoxaemia. Br J Nutr. 2012;108(5):801–9.CrossRef
Metadata
Title
Gut related inflammation and cardiorespiratory fitness in patients with CAD and type 2 diabetes: a sub-study of a randomized controlled trial on exercise training
Authors
Susanne Kristine Aune
Rune Byrkjeland
Svein Solheim
Harald Arnesen
Marius Trøseid
Ayodeji Awoyemi
Ingebjørg Seljeflot
Ragnhild Helseth
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2021
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/s13098-021-00655-2

Other articles of this Issue 1/2021

Diabetology & Metabolic Syndrome 1/2021 Go to the issue

Research

Performance of waist-to-height ratio as a screening tool for identifying cardiometabolic risk in children: a meta-analysis

Research

Microecological preparation combined with an modified low-carbon diet improves glucolipid metabolism and cardiovascular complication in obese patients

Research

The association of sleep duration and metabolic syndrome in the Bandare-Kong cohort study, a cross-sectional survey (finding from PERSIAN cohort study)

Research

Adolescent metabolic syndrome and its components associations with incidence of type 2 diabetes in early adulthood: Tehran lipid and glucose study

Review

Diabetes, obesity, and insulin resistance in COVID-19: molecular interrelationship and therapeutic implications

Research

Liraglutide to Improve corONary haemodynamics during Exercise streSS (LIONESS): a double-blind randomised placebo-controlled crossover trial
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits